NCT01441947View on ClinicalTrials.gov

Cabozantinib in Women With Metastatic Hormone-Receptor-Positive Breast Cancer

PHASE2CompletedINTERVENTIONAL
Enrollment

68

Participants

Timeline

Start Date

October 31, 2011

Primary Completion Date

December 12, 2016

Study Completion Date

August 9, 2019

Conditions
Breast Cancer
Interventions
DRUG

Cabozantinib

Given orally daily with a starting dose of 40 mg

DRUG

Fulvestrant

Given intramuscularly 500 mg on Days 1 and 15 of the first 28 day cycle, then on Day 1 only each cycle after

Trial Locations (4)

10065

Memorial Sloan Kettering Cancer Center, New York

02115

Beth Israel Deaconess Medical Center, Boston

Dana Farber Cancer Institute, Boston

02214

Massachusetts General Hospital, Boston

Sponsors

Collaborators (1)

Exelixis
All Listed Sponsors
collaborator

Exelixis

INDUSTRY

lead

Massachusetts General Hospital

OTHER